AnteoTech Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
17
- Stock Symbol
-
ADO
- Investments
-
1
AnteoTech General Information
Description
AnteoTech Ltd is a biotechnology company engaged in the development of specialty products and services and end-user diagnostic products focused on the Battery and Life Science diagnostics markets. Its key areas are the Energy and Life Science Division. The company is developing four products named AnteoX, Ultranode, AnteoBind NXT, and AnteoBind these products are used in the energy, diagnostic, and medical device markets. The company currently has a single segment which is the development of the AnteoTech IP.
Contact Information
Website
www.anteotech.comCorporate Office
- Unit 4, 26 Brandl Street
- Brisbane Technology Park
- Eight Mile Plains, Queensland 4113
- Australia
Corporate Office
- Unit 4, 26 Brandl Street
- Brisbane Technology Park
- Eight Mile Plains, Queensland 4113
- Australia
AnteoTech Timeline
AnteoTech Stock Performance
As of 21-Mar-2025, AnteoTech’s current market cap is $25.6M with 2.71B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $25.6M | 2.71B | 2.03M |
AnteoTech Financials Summary
As of 31-Dec-2024, AnteoTech has a trailing 12-month revenue of $489K.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 25,420 | 30,345 | 53,341 | 82,647 |
| Revenue | 489 | 302 | 246 | 551 |
| EBITDA | (5,012) | (5,110) | (7,815) | (7,327) |
| Net Income | (5,753) | (5,820) | (8,507) | (7,766) |
| Total Assets | 7,175 | 6,270 | 3,550 | 10,500 |
| Total Debt | 1,410 | 1,560 | 865 | 711 |
AnteoTech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AnteoTech Comparisons
Industry
Financing
Details
AnteoTech Competitors (13)
One of AnteoTech’s 13 competitors is Merck, a Corporation company based in Darmstadt, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck | Corporation | Darmstadt, Germany | ||||
| Dow | Corporate Backed or Acquired | Midland, MI | ||||
| R&D Systems | Corporate Backed or Acquired | Minneapolis, MN | ||||
| VWR International | Formerly PE-Backed | Radnor, PA | ||||
| Actylis | Private Equity-Backed | Port Washington, NY |
AnteoTech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AnteoTech Patents
AnteoTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016100182-A4 | Apparatus and methods for high avidity binding of interfering species in sample analysis | Inactive | 19-Feb-2015 | ||
| FR-3005978-B1 | Clamp type device | Inactive | 27-May-2013 | ||
| FR-3005978-A1 | Clamp type device | Active | 27-May-2013 | ||
| EP-1966603-A1 | Binding of molecules | Inactive | 30-Dec-2005 | ||
| EP-1773866-B1 | Use of metal complexes | Active | 02-Jul-2004 | C07K17/06 |
AnteoTech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AnteoTech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AnteoTech Acquisitions (1)
AnteoTech’s most recent deal was a Merger/Acquisition with DIAsource for . The deal was made on 12-Jan-2016.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DIAsource | 12-Jan-2016 | Merger/Acquisition | Diagnostic Equipment |
AnteoTech ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
26.05 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,784
Rank
Percentile
Pharmaceuticals
Industry
of 955
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 68
Rank
Percentile
AnteoTech Exits (1)
AnteoTech’s most recent exit was on 12-Jan-2016 from DIAsource. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| DIAsource | 12-Jan-2016 | Completed |
|
AnteoTech FAQs
-
When was AnteoTech founded?
AnteoTech was founded in 1995.
-
Where is AnteoTech headquartered?
AnteoTech is headquartered in Eight Mile Plains, Australia.
-
What is the size of AnteoTech?
AnteoTech has 17 total employees.
-
What industry is AnteoTech in?
AnteoTech’s primary industry is Biotechnology.
-
Is AnteoTech a private or public company?
AnteoTech is a Public company.
-
What is AnteoTech’s stock symbol?
The ticker symbol for AnteoTech is ADO.
-
What is the current market cap of AnteoTech?
The current market capitalization of AnteoTech is $25.6M.
-
What is AnteoTech’s current revenue?
The trailing twelve month revenue for AnteoTech is $489K.
-
Who are AnteoTech’s competitors?
Merck, Dow, R&D Systems, VWR International, and Actylis are some of the 13 competitors of AnteoTech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
